BAM
RNAC icon

Belpointe Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Belpointe Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-947
Closed -$18.5K – 916
2024
Q1 		$18.5K Hold
947
– – ﹤0.01% 783
2023
Q4 		$19.6K Buy
947
+67
+8% +$2K ﹤0.01% 701
2023
Q3 		$28K Buy
+880
New +$29.4K ﹤0.01% 645
2023
Q2 		– Sell
-321
Closed -$13.4K – 2765
2023
Q1 		$13.4K Buy
321
+30
+10% +$1.41K ﹤0.01% 2545
2022
Q4 		$9.87K Buy
+291
New +$12.4K ﹤0.01% 2623

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Belpointe Asset Management's RNAC Position: Q2 2024 in Review

Belpointe Asset Management sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 947 shares — an estimated $18.5K sold.

Belpointe Asset Management first reported a position in RNAC in Q4 2022 and held it in 5 quarters. The position peaked at $28K in Q3 2023. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Belpointe Asset Management reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Belpointe Asset Management sold 947 Cartesian Therapeutics shares in Q2 2024, an estimated $18.5K.
  • Belpointe Asset Management first reported a position in Cartesian Therapeutics in Q4 2022 and held it in 5 quarters.
  • Belpointe Asset Management's Cartesian Therapeutics position peaked at $28K in Q3 2023.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Belpointe Asset Management's 13F filing for Q2 2024, filed 2 Aug 2024.